Checkpoint Therapeutics Inc (NASDAQ: CKPT) open the trading on Wednesday, with a bit cautious approach as it glided -6.69% to $3.21, before settling in for the price of $3.44 at the close. Taking a more long-term approach, CKPT posted a 52-week range of $1.38-$4.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of -46.76% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 26.32%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 72.24%. This publicly-traded company’s shares outstanding now amounts to $45.10 million, simultaneously with a float of $37.81 million. The organization now has a market capitalization sitting at $156.75 million. At the time of writing, stock’s 50-day Moving Average stood at $3.65, while the 200-day Moving Average is $2.51.
Checkpoint Therapeutics Inc (CKPT) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Checkpoint Therapeutics Inc’s current insider ownership accounts for 22.57%, in contrast to 15.76% institutional ownership. According to the most recent insider trade that took place on Dec 18 ’24, this organization’s CEO, President and Director sold 602,167 shares at the rate of 3.87, making the entire transaction reach 2,330,386 in total value, affecting insider ownership by 3,414,813. Preceding that transaction, on Dec 19 ’24, Company’s CEO, President and Director sold 220,230 for 3.38, making the whole transaction’s value amount to 744,377. This particular insider is now the holder of 3,194,583 in total.
Checkpoint Therapeutics Inc (CKPT) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Checkpoint Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 72.24% and is forecasted to reach -0.32 in the upcoming year.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Trading Performance Indicators
Let’s observe the current performance indicators for Checkpoint Therapeutics Inc (CKPT). It’s Quick Ratio in the last reported quarter now stands at 0.29. The Stock has managed to achieve an average true range (ATR) of 0.33. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3135.00.
In the same vein, CKPT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.44, a figure that is expected to reach -0.17 in the next quarter, and analysts are predicting that it will be -0.32 at the market close of one year from today.
Technical Analysis of Checkpoint Therapeutics Inc (CKPT)
[Checkpoint Therapeutics Inc, CKPT] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 48.72% While, its Average True Range was 0.31.
Raw Stochastic average of Checkpoint Therapeutics Inc (CKPT) in the period of the previous 100 days is set at 47.13%, which indicates a major rise in contrast to 6.82% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 88.91% that was higher than 68.55% volatility it exhibited in the past 100-days period.
